Cardiovascular collaboration
Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.
The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.
Jian Zhou Medal recognises anaesthesia, blood pressure research
The Australian Academy of Health and Medical Sciences has announced Professor Britta Regli-von...
Australian among 2025 Nobel Prize winners
The first of the 2025 Nobel Prizes have been announced — and this year's awards...
ATSE elects its next President, 2025 Fellows
The Australian Academy of Technological Sciences and Engineering (ATSE) has elected 35 new...
